All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-GD2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target GD2. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-GD2 antibody linked to CD3ζ and CD28 signaling domains. And the vector product was designed for the treatment of neuroblastoma.
CAR Construction : huK666 scfv-CD28-CD3ζ Fig.1 Depletion of autologous neuroblastoma (NBL) cells in infiltrated bone marrow (BM) by GD2-CART cells. Example on the left and degree of depletion for each sample on the right Straathof, K., Flutter, B., Wallace, R., Jain, N., Loka, T., Depani, S., ... & Anderson, J. (2020). Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma. Science translational medicine, 12(571), eabd6169. |
CAR Construction : huK666 scfv-CD28-CD3ζ Fig.2 GD2-CART in vivo expansion. Shown is the detection of 1RG-CART cells by qPCR expressed as copies/ug of DNA at indicated time points after CAR-T cell infusion for the six patients treated on DL4 and DL5. Straathof, K., Flutter, B., Wallace, R., Jain, N., Loka, T., Depani, S., ... & Anderson, J. (2020). Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma. Science translational medicine, 12(571), eabd6169. |
CAR Construction : huK666 scfv-CD28-CD3ζ Fig.3 GD2-CART in vivo expansion. Shown is the detection of 1RG-CART in peripheral blood by flow cytometry for the six patients treated on DL4 and DL5. Straathof, K., Flutter, B., Wallace, R., Jain, N., Loka, T., Depani, S., ... & Anderson, J. (2020). Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma. Science translational medicine, 12(571), eabd6169. |
CAR Construction : huK666 scfv-CD28-CD3ζ Fig.4 GD2-CART in vivo expansion. Shown is the percentage of CD3+/QBEnd10+ cells of CD45+/7-AAD- cells in peripheral blood at day 0 (D0) and at indicated time points after 1RG-CART administration for patients 25/010, 25/013, and 25/018. Straathof, K., Flutter, B., Wallace, R., Jain, N., Loka, T., Depani, S., ... & Anderson, J. (2020). Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma. Science translational medicine, 12(571), eabd6169. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-GD2 (huK666) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-LC007). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION